Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Prif Awduron: Antonio Lacquaniti (Awdur), Patrizio Pasqualetti (Awdur), Teresa Casuscelli di Tocco (Awdur), Susanna Campo (Awdur), Stefania Rovito (Awdur), Maurizio Bucca (Awdur), Antonino Ragusa (Awdur), Paolo Monardo (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...